What should you know about INRGSS neuroblastoma?

INRGSS stands for the International Neuroblastoma Risk Group Staging System. It uses scans taken before treatment to assess where the tumour is, whether it has spread, and whether image-defined risk factors make an operation more difficult or hazardous. Doctors combine this stage with the child’s age, tumour biology, laboratory findings, and response to treatment when estimating risk and choosing care.

A stage is not a prediction of one child’s future on its own. The same stage can be managed differently when biology, symptoms, or treatment response differs. Ask the team to explain the exact findings on the scan report in everyday language.

The specialist team may recommend further imaging, a biopsy, urine or blood tests, and review of tumour biology. Treatment can include chemotherapy to shrink disease, surgery when removal is appropriate, or targeted radioisotope therapy in selected situations. Plans are usually discussed by paediatric oncology, surgery, radiology, and other specialists together.

Contact the treating team urgently for difficulty breathing, severe pain, new weakness, inability to walk, repeated vomiting, unusual sleepiness, a swollen abdomen, or reduced urine. A child receiving treatment also needs prompt advice for fever or a sudden change in behaviour, eating, or drinking.

What is the INRGSS stage and which scan findings determine it? What are the tumour’s biological features? Is surgery planned now or after other treatment? Which side effects should prompt a same-day call?